跳至主要内容
临床试验/NCT07345338
NCT07345338Enrolling By Invitation不适用

Mainstreaming Genetic Testing for Non-Ischemic Cardiomyopathy in Western Canada: A Family-Centered and Genome-First Approach to a Common and Life-Threatening Cardiomyopathy

Thomas Roston4 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2026年2月2日最近更新:
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
300
试验地点
4
主要终点
Uptake of genetic testing for non-ischemic cardiomyopathy (NICM)

研究概览

简要总结

Heart muscle disorders are a common cause of heart failure: a life-threatening condition that can cause dangerous abnormal heart rhythms (arrhythmia) and a buildup of fluid in the body (edema). In British Columbia (BC) and Alberta, patients with heart failure are cared for in specialized Heart Function Clinics (HFC). Providers in these clinics rapidly diagnose and treat heart failure because early treatment prevents death and disability. In some situations, particularly in young people, heart failure is caused by abnormalities in the genetic blueprint of the heart muscle - this is present at birth and passed down within families (i.e. hereditary). The investigators can diagnose this genetic abnormality by a simple blood or saliva test, which allows for better treatment of patients and diagnosis of family members to protect against heart failure and death. In BC and Alberta, people suspected of having this form of heart failure must be referred to highly specialized programs to receive genetic testing, as these healthcare systems currently do not offer genetic testing through HFCs. However, HFC providers are unaware or discouraged to refer patients because of very long waitlists of these programs. In this study, the investigators want to educate, enable, and empower HFC cardiologists to order genetic testing for heart failure. If such an intervention demonstrates success in this study, patients will no longer have to wait for up to 3 years to see a genetic specialist. Patients will be diagnosed and treated earlier, and their family members who might be in danger of having the condition can be informed more quickly. The investigators aim to leverage this study to encourage healthcare leadership to facilitate more timely access to genetic testing by showing the positive impact on health outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older
  • Clinical eligibility for non-ischemic cardiomyopathy/dilated cardiomyopathy (NICM/DCM) genetic testing, per existing clinical criteria in each respective province a. BC sites - presence of NICM/DCM with at least one of the following: i. Family history of NICM/DCM ii. Evidence of conduction disease iii. Arrhythmia (Ventricular or atrial) iv. Unexplained cardiomyopathy under 70 years v. Suggestive syndrome(s)
  • Alberta sites - Left ventricular ejection fraction of less than 50% and any degree of left or right ventricular dilation

排除标准

  • Previously known genetic result that explains NICM/DCM
  • Under age 18 years
  • Declines genetic testing

研究组 & 干预措施

Mainstreamed Genetic Testing through Heart Function Clinics

Experimental

Mainstreamed genetic testing offered directly by the Heart Function Clinic cardiologist with video-based genetic counselling tools

干预措施: Health service delivery change (Other)

Traditional Referral Pathway for Genetic Testing

No Intervention

Traditional referral pathway to a specialized cardiac genetics clinic

结局指标

主要结局

Uptake of genetic testing for non-ischemic cardiomyopathy (NICM)

时间窗: Through 12 months after first participant enrollment

Proportion of eligible patients who complete clinical genetic testing for non-ischemic cardiomyopathy (NICM) following referral from a Heart Function Clinic.

Time to genotypic diagnosis

时间窗: Up to 12 months after consent for genetic testing is provided.

Time (in days) from the date informed consent for genetic testing is signed to the date genetic test results are returned.

次要结局

  • Proportion of participants with a change in clinical management following genetic test results(Up to 12 months after return of genetic test results)
  • Patient-reported satisfaction, knowledge, and decision quality related to genetic testing(At 12 months after first participant enrollment)
  • Proportion of participants with a change to family screening recommendations following genetic test results(Up to 12 months after return of genetic test results)

研究者

发起方
Thomas Roston
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Thomas Roston

Principal Investigator

Cardiology Research UBC

研究点 (4)

Loading locations...

相似试验